Caram MEV, Oerline MK, Dusetzina S, et al. - In this study, coping and material measures of the financial hardship of these therapies were tested among patients with Medicare Part D coverage. Researchers conducted a retrospective cohort study including a 20% sample of Medicare Part D enrollees who had undergone treatment with abiraterone or enzalutamide between July 2013 and June 2015. The study population consisted of 4,153 patients who filled abiraterone or enzalutamide prescriptions through Medicare Part D in 228 hospital referral regions. The substantial differences were found in the adherence rate and out‐of‐pocket payments among Medicare Part D beneficiaries who were prescribed abiraterone and enzalutamide. The data exhibited that sociodemographic patient and regional factors were found to be correlated with both adherence and out‐of‐pocket payments.